Sarepta Therapeutics, Inc. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
5 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 3 with minor changes only.
- Minor: SRP-1005 · Huntington's Disease Trial sites expanded: 4 → 8 locations
- Notable: ENHANCE · ELEVIDYS · Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting Start date pushed from Oct 30, 2026 to Nov 30, 2026
- Minor: MIS51ON · High Doses of Eteplirsen · Duchenne Muscular Dystrophy (DMD) Trial completed
- Minor: EVOLVE · Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice Trial sites expanded: 20 → 23 locations
- Notable: ENDURE · Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care · Duchenne Muscular Dystrophy Primary completion moved earlier from Dec 31, 2029 to Dec 31, 2028
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 3 | |
| Phase 1/2 | 2 | |
| Phase 3 | 3 | |
| Phase 4 | 1 |
Not charted: 3 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials
Duchenne Muscular Dystrophy (6) · Dementia (1) · Heart Disease (1) · Huntington's Disease (1)
Get alerts when Sarepta Therapeutics, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.